PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2178747
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 2178747
According to Stratistics MRC, the Global NAD+ Wellness Supplements Market is accounted for $0.9 billion in 2026 and is expected to reach $2.4 billion by 2034 growing at a CAGR of 13.0% during the forecast period. NAD+ wellness supplements are ingestible nutritional products formulated to support cellular nicotinamide adenine dinucleotide levels, a coenzyme central to energy metabolism and cellular repair. They contain nicotinamide riboside, nicotinamide mononucleotide, niacin, and nicotinamide, which serve as precursors that the body converts into NAD+. These supplements are delivered as capsules, tablets, powders, gummies, and liquid drops, and are consumed daily by general wellness buyers, active adults, and older adults seeking cellular energy, healthy ageing, metabolic, recovery, and cognitive support.
Longevity Science Consumer Interest
Growing mainstream engagement with longevity research is driving demand for supplements positioned around cellular energy and healthy ageing. Media coverage of NAD+ decline with age, together with wellness influencer education, has introduced precursor compounds to premium supplement buyers. Brands publish clinical work on bioavailability and cellular markers, which strengthens credibility and supports premium pricing. This science-forward positioning expands shelf presence across specialty supplement retail and brand-owned e-commerce, thereby sustaining steady volume growth across developed markets.
Regulatory Classification Uncertainty
NAD+ precursor ingredients face varying regulatory classification across jurisdictions, with some authorities treating nicotinamide mononucleotide as a novel food requiring pre-market authorization while others permit sale as a dietary supplement. This inconsistency complicates cross-border distribution, forces reformulation for specific markets, and delays launches. Permissible claims are also restricted, since supplements cannot imply treatment of age-related conditions. These constraints increase compliance costs and slow category expansion, particularly in European and several Asian markets.
Combination Longevity Formulations
Pairing NAD+ precursors with complementary actives such as resveratrol, spermidine, and urolithin A creates opportunity for brands to differentiate through multi-pathway longevity positioning. Combination formulas support higher price points and address consumers seeking consolidated daily regimens rather than single-ingredient products. Subscription models reinforce adherence and generate recurring revenue. As clinical substantiation improves and suppliers standardize precursor grades, combination formulations can capture premium demand across specialty retail and practitioner channels.
Substitution by Established B Vitamins
Niacin and nicotinamide have long been available as inexpensive B-vitamin supplements, which reduces willingness among price-sensitive consumers to pay premiums for branded NAD+ precursor products. Many buyers perceive these commodity forms as functionally equivalent, particularly when clinical differentiation is not clearly communicated. If mainstream supplement brands add NAD+ positioning to existing B-vitamin lines at lower cost, specialist products may face margin pressure. Consequently, brands must substantiate bioavailability and cellular benefits to defend pricing.
The pandemic heightened consumer interest in preventive health and cellular resilience, which extended into longevity supplements as buyers sought overall wellness support. During the crisis, e-commerce subscriptions for NAD+ precursors expanded rapidly while pharmacy footfall declined. Post-pandemic, sustained wellness habits and renewed interest in healthy ageing have reinforced demand, while brands strengthened clinical substantiation and expanded convenient formats such as gummies and liquid drops to improve adherence.
The Nicotinamide Riboside Supplements segment is expected to be the largest during the forecast period
The Nicotinamide Riboside Supplements segment is expected to account for the largest market share during the forecast period, due to its early commercial availability, extensive bioavailability research, and established consumer recognition within the NAD+ category. Nicotinamide riboside integrates readily into capsules and tablets, which supports broad distribution across specialty retail and e-commerce. As brands expand combination longevity formulas, this precursor remains the anchor ingredient that drives trial and repeat purchase, thereby sustaining leading revenue share across the market.
The Gummies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Gummies segment is predicted to witness the highest growth rate, driven by consumer preference for convenient, pleasant-tasting formats that improve daily adherence among younger buyers. Gummies reduce pill fatigue and support subscription models, while allowing brands to combine NAD+ precursors with complementary longevity actives in a single serving. As formulators improve active loading and stability in gummy matrices, launches multiply across pharmacy and e-commerce channels, making this the fastest-growing product form segment.
During the forecast period, the North America region is expected to hold the largest market share, due to high supplement consumption, strong longevity research ecosystems, and widespread availability of NAD+ precursor products across specialty retail and online channels. The United States dominates regional revenue, supported by brands investing in clinical substantiation and convenient formats. Established dietary supplement pathways and active venture funding for wellness startups further reinforce North America's leading position in NAD+ wellness supplements.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly ageing populations, rising disposable incomes, and strong interest in healthy-ageing nutrition across Japan, China, South Korea, and India. Consumers readily adopt nicotinamide riboside and mononucleotide products, while local brands expand gummy and powder formats. Growing e-commerce penetration and nutrition clinic networks further support adoption, making Asia Pacific the fastest-growing regional market for NAD+ wellness supplements.
Key players in the market
Some of the key players in NAD+ Wellness Supplements Market include Nestle S.A., Danone S.A., Abbott Laboratories, Amway Corporation, Herbalife Ltd., USANA Health Sciences, Inc., Nature's Sunshine Products, Inc., Jamieson Wellness Inc., Haleon plc, Bayer AG, Glanbia plc, Blackmores Limited, NOW Health Group, Inc., Thorne HealthTech, Inc., Pharmavite LLC, and Swisse Wellness Pty Ltd.
In October 2026, Thorne HealthTech, Inc. launched a nicotinamide riboside and resveratrol combination capsule supported by bioavailability testing, distributed through practitioner channels and brand-owned e-commerce across North American and European markets.
In September 2026, Haleon plc expanded its healthy-ageing portfolio with nicotinamide mononucleotide tablets and powders positioned for cellular energy support, targeting older adults through pharmacies and online marketplaces across Europe and Asia Pacific.
In August 2026, Blackmores Limited introduced NAD+ precursor gummies and liquid drops formulated for daily adherence, distributed through specialty retailers and e-commerce platforms with practitioner education programs across Australia and Southeast Asia.
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Netherlands
Belgium
Sweden
Switzerland
Poland
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Thailand
Malaysia
Singapore
Vietnam
Rest of Asia Pacific
South America
Brazil
Argentina
Colombia
Chile
Peru
Rest of South America
Rest of the World (RoW)
Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
Africa
South Africa
Egypt
Morocco
Rest of Africa
Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.